Knew Covid had been engineered to make it infectious to humans but were told to shut-up'

Knew Covid engineered to make it infectious to humans but was silenced

Covid was the name of the disease caused by a new coronavirus, which led to a new respiratory disease in Wuhan, China, which rapidly spread throughout the…

www.express.co.uk

Whilst looking closely for these features it became immediately obvious that this virus was extremely unlikely to have come from a bat, even via another animal, as it had inserts around the receptor binding region and - a feature not present on any similar virus - that would make it more infectious.

For the liers and deniers, your rct!

Vitamin D3 Supplementation at 5000 IU Daily for the Prevention of Influenza-like Illness in Healthcare Workers: A Pragmatic Randomized Clinical Trial

Cooper Health System Clinical Trial Results: Vitamin D Reduces Healthcare Workers’ Incidence of Influenza-like Illness

A growing body of literature suggests that vitamin D supplementation taken consistently over months can reduce the incidence of acute respiratory infections,…

www.trialsitenews.com

A growing body of literature suggests that vitamin D supplementation taken consistently over months can reduce the incidence of acute respiratory infections, most prominently when the supplement is taken in daily doses rather than large amounts at once. Research has revealed some benefits of vitamin D as a regimen to either help prevent SARS-CoV-2, the virus behind COVID-19, or reduce its severity, but apex research institutes, such as the National Institute of Health, declare insufficient evidence to actually recommend this supplement as a treatment. This recent study led by investigators with Cooper University Health and collaborators tested the hypothesis that daily vitamin D supplementation in healthcare workers leads to reduced incidence of COVID-19-related influenza-like illness (ILI) as well as reductions in non-COVID ILI when compared to other healthcare workers. In what can be considered a significant finding, the study investigators report that taking vitamin D (5000 IU) reduces influenza-like illness in healthcare workers. What about reducing the incidence of COVID-19? When compared to the control group during this study, the study team found that the participants in the vitamin D3 group did experience a lower rate of ILI due to COVID-19, however, the results were not statistically powered. The general takeaway: Taking vitamin D (5000 IU) as part of a regular regimen reduces influenza-like illness in healthcare workers.

Background

The team of investigators working at Cooper Health System conducted this prospective study over a 13 month period evaluating A) if daily vitamin D3 can prevent ILI in healthcare workers and B) study if daily vitamin D can prevent COVID-19 ILI in healthcare workers. Subjects were randomly selected and ultimately consented for the 9-month daily vitamin D3 regimen.

The New Jersey-based team employed the use of Zelen’s design for the study, a practical clinical trial design where the participants are randomized before providing informed consent.

Once randomized, the clinical investigators randomized participants to the interventional arm for consent and subsequent enrollment. Based on a series of mathematical models, the researchers expected that 34.4% of the control group would report to Employee Health for at least one respiratory infection.

The study was sponsored by Cooper Health System, a Camden, New Jersey-based academic medical center founded in 1887 by a family of the Quaker physician Richard M. Cooper. The Won Sook Chung Foundation also supported the study (NCT04596657).

See image below for representation of Zelen's design-inspired study.

Findings

The group assumed a 6% reduction in at least one acute respiratory infection associated with the vitamin D regimen. Employing use of a statistical one-tailed α of 0.05 and β of 0.15, 859 subjects were projected in the vitamin D supplementation and control arms.

The initial target age of 52 and up was modified due to the all-too-common patient recruitment challenge. Thus, the study team modified the protocol to widen eligibility for all persons between the age of 18 to 52.

The intervention involved oral gel capsules at a dose of 5000 IU per day. Participants were included in the intervention group analysis if they completed at least 2 months of the regimen.

The final control group totaled 2827 healthcare workers. The investigators, represented by corresponding author and anesthesiologist Dr. Ludmil Mitrev, report that “Vitamin D3 5000 IU supplementation was associated with a lower risk of ILI as well as lowering the incidence rate for non-COVID-19 ILI. The COVID-19 ILI wasn’t statistically different.”

Results of the Cooper Health System sponsored study titled: “Vitamin D3 Supplementation to Prevent Respiratory Tract infections”---Vitamin D3 5000 IU supplementation associates with:

Category of ILI

Vitamin D statistical results

Lower Risk of ILI

incidence rate difference: −1.7 × 10−4/person-day, 95%-CI: −3.0 × 10−4 to −3.3 × 10−5/person-day, p = 0.015

lower incidence rate for non-COVID-19 ILI

incidence rate difference: −1.3 × 10−4/person-day, 95%-CI −2.5 × 10−4 to −7.1 × 10−6/person-day, p = 0.038

COVID-19 ILI incidence

incidence rate difference: −4.2 × 10−5/person-day, 95%-CI: −10.0 × 10−5 to 1.5 × 10−5/person-day, p = 0.152—not statistically different

299 healthcare workers were ultimately enrolled between October 27, 2020, and January 31, 2021, in the intervention group. 255 of the subjects ultimately completed vitamin D regimen for at least two months and were included in the study team’s final study analysis. During the study, a control group consisting of 2892 randomly selected healthcare system employees were monitored. A total of 578 control group participants offered data for analysis, including demographic and clinical information by the end of the study. Study participant average age was slightly higher in the control group (50 vs. 47), and an average adherence rate of the intervention equaled 87% with a median rate of 91%. Observation time included:

Study Group

Observation time (person days)

Intervention

49,147

Control Group

861,141

The results were segmented, analyzed, and presented as: 1) All-influenza like illness (ILI), 2) COVID-19 influenza like illness and 3) Non-COVID influenzas like illness. See the tables for some comparisons—first for Absolute Incidence Rate Differences:

Illness

Intervention Group

Incidence Rate

Control Group

Incidence Rate

Absolute Incidence Rate Difference

95%-CI

P-Value

ALL ILI

6.104 × 10−5

2.288 × 10−4

−1.677 × 10−4

−3.025 × 10−4

to −3.3 × 10−5

0.0147

COVID-19 ILI

0.0

4.181 × 10−5

−4.181 × 10−5

−9.897 × 10−5

to 1.536 × 10−5

0.1517

Non-COVID-19 ILI

6.104 × 10−5

1.916 × 10−4

−1.306 × 10−4

2.541 × 10−4

to −7.1 × 10−6

0.0382

Relative Incidence Rate:

Illness

Relative Incidence Rate

95%-CI

P-Value

ALL ILI

2.668 × 10−1

5.456 × 10−2

to 7.913 × 10−1

0.0060

COVID-19 ILI

NA

NA

NA

Non-COVID-19 ILI

3.186 × 10−1

6.503 × 10−2

to 9.474 × 10−1

0.0229

Overall, the Cooper Health System led trial site team reports that “daily vitamin D3 supplementation was associated with overall reduced ILI.”

Contributing to these findings were the deltas between non-COVID ILI incidence rates during the study term as well as COVID-19 ILI incidence rates during the overall study duration when these New Jersey-based workers had not yet received any COVID-19 vaccines.

Do the recent findings support a growing body of research supporting the use of vitamin D against influenza-like illness?

Yes. The study authors point to other supporting research such as Joliffe et al which found that vitamin D supplementation reduced the risk of respiratory tract infections as compared to the placebo with an associated odds ratio (OR) of 0.92 (95% CI 0.86–0.99). This particular study reports results are superior when vitamin D is taken daily versus intermittent or single-dose regimens.

Does daily vitamin D3 supplementation reduce ILI due to COVID-19 in healthcare workers?

A secondary endpoint of the study, the authors first introduced two bodies of evidence, one suggesting vitamin D3 supplementation may help alleviate COVID-19, and another parallel body suggests no significant impact. Here the team made some adjustments as compared to other studies including the use of vitamin D3 5000 IU versus 3200 IU and a requirement that the participant take for 2 months.

The study authors reported that the group of participants receiving the regimen “experienced a non-statistically significant lower rate of ILI due to COVID-19.” This means they recommend further study, with appropriate scale for statistical power.

What’s an important takeaway?

A significant advancement for the use of this supplement, the Cooper Health System-based team declared in their study report: “Daily vitamin D3 supplementation is an inexpensive and safe intervention. The results of the present study suggest that daily vitamin D3 supplementation can be recommended to reduce the incidence of ILI in healthcare workers.”

The study team concludes that taking vitamin D (5000 IU) reduces influenza-like illness in healthcare workers.

Do the authors claim that vitamin D3 directly reduces COVID-19?

No. A sufficiently powered study to assess the reduction in COVID-19 breakthrough infections is recommended.

About the Trial Site Center

Cooper Health System, part of Cooper University Health Care, positions itself as the leading academic health system in South Jersey, providing access to primary, specialty, tertiary, and urgent care, all within one complete health system. With over 8,500 employees, including 800+ physicians practicing in more than 75 specialties, the health system maintains hospitals throughout the region, handling the most complex and critically ill and injured patients. The Cooper Research Institute fosters research within the Cooper Health System by providing the faculty, residents, fellows, nurses, and allied health professionals of Cooper with the support and services required to promote and to successfully develop and conduct investigator-initiated and sponsor-initiated clinical research, and to attract and manage government, foundation, and industry support.

The Cooper Research Institute works in cooperation with Cooper Medical School of Rowan University to foster the growth of student-centric research in the areas of medical education, the science of healthcare delivery and population health, and targeted translational research, capitalizing on the institutional strengths and expertise of both organizations.

Quote from Fm1

Cooper University Health and collaborators tested the hypothesis that daily vitamin D supplementation in healthcare workers

The link :: https://www.medrxiv.org/conten…09.16.22280047v1.full.pdf

In the intervention group, no workers had a positive COVID-19 PCR test during the observation

period, while in the control group 36 workers had at least 1 positive COVID-19 PCR test.

Quote from Wyttenbach

The link :: https://www.medrxiv.org/conten…09.16.22280047v1.full.pdf

One more thing: They state :: In the intervention group, three workers had at least 1 episode of ILI, while 197 workers in the
control group had at least 1 episode of ILI.

This is highly significant!! But their conclusion is::

We found that compared to the control group, the vitamin D3 supplementation group experienced a non-statistically significant lower rate of ILI due to COVID-19!!! So exact reading is needed! This is just a special case.

Quote from Wyttenbach

One more thing: They state :: In the intervention group, three workers had at least 1 episode of ILI, while 197 workers in the
control group had at least 1 episode of ILI.

This is highly significant!! But their conclusion is::

We found that compared to the control group, the vitamin D3 supplementation group experienced a non-statistically significant lower rate of ILI due to COVID-19!!! So exact reading is needed! This is just a special case.

Deceptively written conclusions seem to now be the norm since Covid arrived. This study along with the John Campbell video provides all the information you need to see vitamin d is the key to a long healthy life but it's a constant battle to maintain sufficient levels and it starts at conception! Diet and Supplementation of key vitamins and minerals keeps big pharma away! And they know it!!!

Sequel to "directed evolution"..

Directed transparency from Pfizer..

"

the company would like to set the record straight.
Seek medical attention right away if you have any of the following symptoms:

Difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness.

.

GABA: A Panacea Against COVID-19 Variants?

GABA: A Panacea Against COVID-19 Variants?

The protective effects of gamma-aminobutyric acid (GABA) against two very different beta coronaviruses (SARS-CoV-2 and MHV-1) suggest by some…

www.trialsitenews.com

The protective effects of gamma-aminobutyric acid (GABA) against two very different beta coronaviruses (SARS-CoV-2 and MHV-1) suggest by some proponents that it may provide a generalizable off-the-shelf therapy to help treat diseases induced by new SARS-CoV-2 variants and novel coronaviruses. Proponents suggest GABA may be particularly useful against those that evade immune responses and antiviral medications. GABA is inexpensive, safe for human use, and stable at room temperature, making it an attractive candidate for testing in clinical trials. TrialSite has previously reported on medical advancements utilizing GABA for conditions such as Type 2 diabetes, diseases of the nervous system, and depressive symptoms.

Serving as the chief inhibitory neurotransmitter in the developmentally mature mammalian central nervous system, GABA helps reduce neuronal “excitability throughout the nervous system.”

We reviewed emerging data accumulated from three studies (Bhat et al., 2010, Tian et al., 2021, and Tian et al., 2022) that investigated GABA’s potential role in coronavirus treatment. These studies utilized animal models since they’ve proven to be an adequate comparison to human models for preclinical research. A reminder that before a medicinal product is approved by regulatory authorities it is supposed to go through rigorous testing in human clinical trials that include three phases.

GABA Reduces Autoimmune Reactions

The recent research builds on existing evidence regarding GABA and its potential uses in immunology. This research used either GABA or GABA-like molecules that also work on the same cellular receptors (GABA receptor agonists).

One example is a study conducted in 2010, that aimed to test if GABA receptor agonists could help with multiple sclerosis symptoms by inducing experimental autoimmune encephalomyelitis (EAE) in mice. The results showed that symptoms, including paralysis, were helped. This could translate to having a positive effect on MS in humans. Also, when the mice were autopsied at the end of the experiment, a reduction in cytokines was found as well as reduced inflammation and nerve damage.

While the study focused on MS, the results hold promise for other autoimmune reactions, including those associated with COVID-19.

GABA Limits Coronavirus-Induced Pneumonia?

Mouse hepatitis virus (MHV) closely resembles the SARS-CoV virus in humans, and research into GABA’s role in coronavirus pneumonia continued with an MHV model in 2021. Mice were injected with MHV-1 and those in the study group were given a GABA receptor agonist while those in the control group were not. The results showed that oral GABA given either before or after the appearance of symptoms very effectively limited MHV-1-induced pneumonitis, severe illness, and death. GABA treatment also reduced viral load in the lungs, suggesting that GABA receptors may provide a new treatment target to limit coronavirus replication.

The study tested two GABA receptor agonists: homotaurine, which is specific for the GABA-A receptor, and baclofen, which is specific for GABA-B receptors. They found that homotaurine significantly reduced the severity of pneumonitis and death rates in MHV-1-infected mice, but baclofen did not. This indicates that the therapeutic effects were brought about primarily through GABA-A receptors.

Since GABA and homotaurine are safe for human consumption, they are promising candidates to help treat coronavirus infections.

GABA Protects against Severe Illness and Death from SARS-CoV-2

The results of the MHV served as a springboard for further investigations into whether targeting GABAA -Rs can provide new avenues to limit severe illness due to infection with SARS-CoV-2 and other novel coronaviruses.

This study confirmed findings from a 2021 study by the same authors at the Department of Molecular and Medical Pharmacology at the University of Southern California Los Angeles (UCLA). The researchers infected mice with the SARS-CoV-2 virus and then, two days later, randomized them into two groups. One group was given plain water, while the other was given water containing GABA.

The researchers found that the GABA treatment protected the infected mice from severe illness and death: at the end of the study, only 22% of the mice who’d been given plain water survived, while 88% of those who’d received GABA survived.

The study demonstrated that GABA administration initiated immediately, or two days post SARS-CoV-2 infection, reduced the lung coefficient index, lung viral load, pneumonitis, and death rate in SARS-CoV-2-infected mice, which all correlate with reducing respiratory symptoms of a COVID-19 infection.

Summary and Implications

These studies provide promising early-stage animal-based evidence that GABA can reduce inflammation, control coronavirus load in the lungs, and protect against severe disease and death in coronavirus infections.

Given that these were all animal studies and equivalent research has not yet been completed on humans, more research is necessary. GABA’s impact on immune cells and lung cells may differ in important ways between mice and humans.

Rigorous clinical trials are needed to determine what benefit, if any, GABA or GABA receptor agonist treatment has in COVID-19 patients, including the time window for treatment and optimum dosage.

A cheap and effective drug such as GABA, available in generic form for as little as 7 cents a dose online, may seem like a dream solution to reduce the threat of COVID-19, as the world prepares to move from the pandemic to an endemic state. However, there are stakeholders who may not see it that way.

TrialSite has documented the intense backlash against ivermectin, another commonly available, cheap and safe treatment. The campaign to shut down ivermectin as a potential COVID-19 treatment has ranged from online ridicule to restricted prescribing regulations, suspending doctors who prescribe it, and rejecting or withdrawing scientific articles from publication. This is despite large amounts of clinical and real-world evidence supporting its effectiveness, as well as its similarity in action to newly-developed drugs such as Paxlovid. As research into GABA progresses, it will be interesting to see the response of health authorities and peer-reviewed journals to this potential panacea.

What Does Gamma Aminobutyric Acid (GABA) Do?

https://www.healthline.com/hea…butyric-acid#What-is-GABA?

Neuronal and Non-Neuronal GABA in COVID-19: Relevance for Psychiatry

Neuronal and Non-Neuronal GABA in COVID-19: Relevance for Psychiatry

Infection with SARS-CoV-2, the causative agent of the COVID-19 pandemic, originated in China and quickly spread across the globe. Despite tremendous economic…

www.mdpi.com

Vitamin D deficiency induces the excitation/inhibition brain imbalance and the proinflammatory shift

Vitamin D deficiency induces the excitation/inhibition brain imbalance and the proinflammatory shift - PubMed

Vitamin D₃ is among the major neurosteroids whose role in developing and adult brain is intensively studied now. Its active form…

pubmed.ncbi.nlm.nih.gov

GABA won't do anything if you are vitamin D deficency. It's all about vitamin D. Vitamin D is the key!

US Mainstream Media Outlet Questions Government Response to Covid Pandemic

US Mainstream Media Outlet Questions Government Response to Covid Pandemic

TrialSite News has reported on how the mainstream media, mostly in Europe, has shifted its coverage of the Covid-19 pandemic. The European news outlets are…

www.trialsitenews.com

TrialSite News has reported on how the mainstream media, mostly in Europe, has shifted its coverage of the Covid-19 pandemic. The European news outlets are specifically dealing with the growing reports of injuries due to the Covid jab. This is a story TrialSite has covered to a point of having a vaccine injury support group on the website. Other perspectives, specifically from members of the medical community like Dr. Paul Offit, have also expressed skepticism in American mainstream media. Now, it appears there’s been a shift in US news coverage of how the Covid pandemic was handled in the United States.

Newsweek Op-Ed Questions Covid Response in the US

Newsweek recently published an opinion piece by Medical Student and doctor, Kevin Bass who believes it’s time for the scientific community to admit its response to the Covid pandemic was wrong and cost lives. Bass writes, “I can see now that the scientific community from the CDC (Centers for Disease Control) to the WHO (World Health Organization) to the FDA (Food and Drug Administration) and their representatives, repeatedly overstated the evidence and misled the public about its own views and policies, including on natural vs. artificial immunity, school closures and disease transmission, aerosol spread, mask mandates, and vaccine effectiveness and safety, especially among the young. All of these were scientific mistakes at the time, not in hindsight. Amazingly, some of these obfuscations continue to the present day.”

Bass expresses his thoughts that the scientific community imposed their idea of how to deal with the pandemic on the public. According to Bass, the scientific community turned the Covid response into a “team sport” and made the pandemic an “us versus them” situation. Scientists, academics, and government officials developed what Bass calls a “monolithic response” to the pandemic and harshly criticized anyone who disagreed with policy. He continues by saying this is a diverse nation with differing opinions, and the government’s pandemic response caused further separation of an already divided nation.

Impact of Covid Response Not Fully Understood

Bass continues, “Our emotional response and ingrained partisanship prevented us from seeing the full impact of our actions on the people we are supposed to serve. We systematically minimized the downsides of the interventions we imposed—imposed without the input, consent, and recognition of those forced to live with them. In so doing, we violated the autonomy of those who would be most negatively impacted by our policies: the poor, the working class, small business owners, Blacks and Latinos, and children. These populations were overlooked because they were made invisible to us by their systematic exclusion from the dominant, corporatized media machine that presumed omniscience.” TrialSite has reported on how race has been a factor in the Covid pandemic in both treatment and death rate.

Taking the official response one step further, Bass makes the point that by not listening and deriding possible alternative medications like ivermectin, many people started believing “conspiracy theories” surrounding the pandemic. “Pandemic policy was created by a razor-thin sliver of American society who anointed themselves to preside over the working class—members of academia, government, medicine, journalism, tech, and public health, who are highly educated and privileged. From the comfort of their privilege, this elite prizes paternalism, as opposed to average Americans who laud self-reliance and whose daily lives routinely demand that they reckon with risk. That many of our leaders neglected to consider the lived experience of those across the class divide is unconscionable.”

Public Trust Needs to be Restored

Bass concludes by writing, “It's clear to me that for public trust to be restored in science, scientists should publicly discuss what went right and what went wrong during the pandemic, and where we could have done better.” Perhaps, one more step has to be taken. There is no question that the government response was influenced by Big Pharma. At some point oversite of the clout of the drug companies on political decisions should be examined.

Can Plant Extracts Effectively Inhibit SARS-CoV-2—The Results of a Portugal Review Study Look Promising

Can Plant Extracts Effectively Inhibit SARS-CoV-2—The Results of a Portugal Review Study Look Promising

Can natural products be used as a means of combating COVID-19? Afterall, plant-based chemistry has been at work in Traditional Chinese Medicine (TCM) for…

www.trialsitenews.com

Can natural products be used as a means of combating COVID-19? Afterall, plant-based chemistry has been at work in Traditional Chinese Medicine (TCM) for centuries, based on plants: long the source of individual molecules and extracts capable of inhibiting/neutralizing several microorganisms, including viruses. In fact, natural extracts have demonstrated potential efficacy against various pathogens in the coronavirus families, although that fact isn’t touted much by mainstream media in the West. But plenty of misinformation associated with this topic continues to circulate across cyberspace. There are reasons medical products are tightly regulated at the national level. Only after careful and systematic research demonstrating safety and effectiveness will such natural products be authorized by relevant authorities. In that spirit, recently, a group of collaborating scientists from Portugal, affiliated with the Mountain Research Institute and the Catholic University of Portugal (Center for Biotechnology and Fine Chemistry), investigated select plant metabolites and their potential therapeutic value targeting SARS-CoV, the virus behind COVID-19. Of particular interest to the Portugal-based scientists, represented by corresponding author Lillian Barros, Ph.D., a biotech engineer with a focus on biotechnology and food chemistry, was a couple of molecules associated with Traditional Chinese Medicine (TCM) as the world’s biggest population depends heavily on this approach targeting COVID-19. In this Portugal-based study, the team studied plant extracts on coronaviruses, discussing results, including the primary inhibition assays and future trends associated with COVID-19.

What are the primary strategies to inhibit or stop SARS-CoV-2, the virus behind COVID-19?

Researchers have determined a couple pathways for therapy to work, including 1) inhibiting of SARS-CoV-2 penetration by preventing SARS-CoV-2 S-ACE2 binding interactions and 2) the inhibiting of protease enzymes such as Mpro (main protease), 3CLpro (3C-like protease) and PLpro (papain-like protease).

Enter this investigation into plant metabolites targeting SARS-CoV-2

The study team centered their investigation on select plants associated with TCM, for example, and the derived molecules that can actually bind with glycoprotein and consequently stop membrane fusion included A) luteolin (11 µM) and TGG (tetra-O-galloyl-β-D-glucose, 5.0 µM), both taken from TCM that do bind with spike glycoprotein. The team looked at other plant-based molecules.

The study team used the SCOPUS database and associated software to better understand a relation between plants and SARS-CoV02. They report about 1504 documents surfaced based on targeted keywords from 2020 to 2022. Selecting output with at least one of the chosen search terms, the team used specialized software to organize output by relevance and relationship.

What’s interesting about plant-based molecules potentially capable of stopping what’s known as cysteine proteases?

It turns out that SARS-CoV-2 thrives thanks to an enzyme called 3CLpro, responsible for the processing of proteins essential for the novel coronaviruses thriving. Hence why, drugs such as Paxlovid fall in the class of 3CLpro inhibition.

Other inhibitors involving both PLpro and 3CLpro identified by the researchers include chalcones, especially chalcone 6 as well. Some properties associated with plans inhibit PLpro with more effectiveness—such as polyphenol compounds taken from the leaves of the paper mulberry tree native to eastern Asia. For example, the following compounds are identified by the researchers as falling in this category (inhibiting PLpro more intensely than against 3CLpro):

broussochalcone A

broussochalcone B

kazinol J

kazinol B

4-hydroxyisolonchocarpin

kazinol A

broussoflavan A

papyriflavonol A

kazinol F

Overall, the team reported in their paper published in MDPI that of the compounds studied, Papyriflavonol A shows superior ability to inhibit PLpro enzyme. While one compound could inhibit both the relevant proteins—PLpro and 3CLpro: Salvia miltiorrhiza Bunge-derived lipophilic tanshinones.

The researchers analyze the plant-based metabolites’ potential for contributing to regimen targeting SARS-CoV-2, including several other examples.

What’s a takeaway?

The scientific literature suggests a definite therapeutic value associated with certain plant extracts, including ones involved in TCM, targeting SARS-CoV-2, the virus behind COVID-19. The Portuguese researchers document a particular interest in bioactive molecules such as alkaloid compounds as well as phenolic substances from chalcones and flavonoids to tannins and lignins to glycosides. Likely, with targeted focus and investment in this plant-based medicinal approach, companies focusing on this area could offer substantially safe and effective, not to mention economical treatments against COVID-19. But would this fit into the biopharmaceutical business model?

What institutions were involved?

Centro de Investigação de Montanha (CIMO), or the Mountain Research Center, affiliated with the Instituto Politécnico de Bragança, Campus de Santa Apolónia located in Bragança, a city in the far northeastern corner of Portugal along with CBQF—Centro de Biotecnologia e Química Fina—Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, Rua de Diogo Botelho, Porto, a coastal city in the northwest of this Southern European nation.

Plant Extracts and SARS-CoV-2: Research and Applications

Plant Extracts and SARS-CoV-2: Research and Applications

The recent pandemic of COVID-19 caused by the SARS-CoV-2 virus has brought upon the world an unprecedented challenge. During its acute dissemination, a rush…

www.mdpi.com

IF you like to download the antitrust lawsuit against TNI. TNI is the union of all big newspaper, channels,Google, facebook, twitter that agreed to stop publishing all fact about e.g. Ivermectin, vaccine damage, the India miracle, the Kerala vaxxine fail...virus origin They forced false claims like vaxxines protect form infection or transmission etc...

‘Trusted News Initiative’ Antitrust Litigation

Related Defender Article Good Morning CHD with the Plaintiffs Good Morning CHD with the Attorneys Filed Complaint Executive Summary Press Release Litigation…

childrenshealthdefense.org

Click the download link in the embedded frames top!

IgA Vasculitis after COVID-19 Vaccination

Autoimmune Conditions Destined to Occur when Cells are Forced to Produce Spike Protein

IgA Vasculitis after COVID-19 Vaccination

Autoimmune Conditions Destined to Occur when Cells are Forced to Produce Spike Protein

petermcculloughmd.substack.com

The human body makes thousands of normal proteins recognized to be our own by the immune system. These proteins maintain housekeeping of the cells, build up structures like muscle, and breakdown other proteins such as digestive enzymes. The beautiful system can go awry when the body recognizes an internal produced protein that is foreign. This is the disastrous result of blunderous groupthink by mRNA “inventors” who conceived of using RNA coding for an abnormal protein to be inserted in the body letting our own cells produce it and then brace for the auto-immune attack.

U.S. Leads in Health Care Spending, But Is Last Among Wealthy Countries for Major Health Outcomes

U.S. Leads in Health Care Spending, But Is Last Among Wealthy Countries for Major Health Outcomes

Despite spending up to four times more on health care than most wealthy nations, the United States lags far behind when it comes to health outcomes, according…

www.trialsitenews.com

Despite spending up to four times more on health care than most wealthy nations, the United States lags far behind when it comes to health outcomes, according to a new report from the nonprofit Commonwealth Fund.

The analysis was led by Munira Gunja, senior researcher for the Commonwealth Fund's International Program in Health Policy and Practice Innovation. In the report, Gunja's team compared health care spending and outcomes in the United States with those of 12 other high-income nations and the averages for 38 Organization for Economic Co-operation and Development (OECD) member nations between January 2020 and December 2021.

In 2021, the U.S. spent 17.8 percent of gross domestic product (GDP) on health care, nearly twice as much as the average OECD country.

Although the U.S. spends more on health care than other nations, it continues to have the highest rates of preventable deaths from diabetes, high blood pressure-related diseases and certain cancers, and the highest rate of people living with multiple chronic conditions, the report found. The obesity rate in the United States is nearly double what is seen in other OECD nations. Despite this, the U.S. is the only country that doesn’t have universal health coverage.

Life expectancy is lowest among wealthy countries: in 2021 Americans lived an average of 77 years of age, which is three years younger than the average among people in other wealthy nations. Provisional data shows life expectancy in the U.S. dropped even further in 2021.

The U.S. also has the lowest life expectancy at birth and the highest maternal and infant mortality. In 2020, there were nearly 24 maternal deaths for every 100,000 live births in the U.S., more than three times the rate in most of the other high-income countries studied.

Americans see physicians less often than people in most other countries and have among the lowest rate of practicing physicians and hospital beds per 1,000 population.

Additionally, people living in the U.S. are more likely to die from physical assault, including gun violence. At 7.4 deaths per 100,000 people, the rate is far above the OECD average of 2.7, and at least seven times higher than all other high-income countries in our study, except New Zealand.

The authors of the report note some suggestions for improving the state of U.S healthcare. As a first step, ensure that everyone has access to affordable care. Not only is the U.S. the only country we studied that does not have universal health coverage, but its health system can seem designed to discourage people from using services, the note. A second step would be to contain costs as other countries have achieved better health outcomes while spending much less on health care overall. A third step is to find better strategies to prevent and manage chronic conditions.

Quote from Fm1

The U.S. also has the lowest life expectancy at birth and the highest maternal and infant mortality.

USA is close to a development country for 80% of its population at the lower end. No education, no adequate salary no rights (layers cost money). It's a shame and both parties (both are FM/R/F mafia) try to force a split with fake arguments. Same as the Romans did. Divide et impera. (Divide and rule) . Crazy people no longer have a clear mind and enough momentum to divert them.

Excess death Is everywhere, no problem????

French Study Probes Morbidity & Mortality Associated with COVID-19 Vaccinated Patients

French Study Probes Morbidity & Mortality Associated with COVID-19 Vaccinated Patients

While COVID-19 vaccination helped reduce morbidity and mortality assuming the appropriate timing of booster doses, researchers in France represented by…

www.trialsitenews.com

While COVID-19 vaccination helped reduce morbidity and mortality assuming the appropriate timing of booster doses, researchers in France represented by corresponding authors Adrien Mirouse and Alice Friol, both with University Hospitals Pitié Salpêtrière - Charles Foix (Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix) and Sorbonne Université in Paris sought out with this study to report the clinical picture, management and outcomes of patients vaccinated against COVID-19 who developed a severe infection requiring ICU admission. Additionally, a secondary endpoint included the comparison of these severe breakthrough cases with critically unvaccinated COVID-19 patients with the hope for contributing to better public policies involving higher-risk patients. Conducting a multicenter cohort study involving severe COVID-19 patients admitted to 15 ICUs across France between January and September 2021, the study team evaluated 100 consecutive vaccinated patients—68% males with a median age of 64. In the patient, pool immunosuppression was reported among 38% of the total. What did they find?

Findings

As reported in Nature: Scientific Reports, 64% of available serologies at ICU admission evidenced an optima antibody level, and a media SOFA score at ICU admission equaled 4 4–6.3], and median PaO2/FiO2 ratio was 84 [69–128] mmHg. What number of patients received high-flow nasal oxygen and non-invasive mechanical ventilation? 79 (79%) and 18 (18%) patients, respectively.

A total of 48 (48%) patients received invasive mechanical ventilation for a media of 11 days [5-19]. With a media ICU length-of-stay at 8 days [4-20], 31 (31%) of these patients died, a high mortality rate.

What other elements were independently associated with mortality of the vaccinated patients? That includes age (OR per 5-years increment 1.38 CI95% [1.02–1.85], p = 0.035) and SOFA at ICU admission (OR 1.40 CI95% [1.14–1.72] per point, p = 0.002).

What about comparisons to the unvaccinated?

The French research team compared the vaccinated cohort to an unvaccinated cohort totaling 1316 patients, 72% of them were males with a median age of 63. Some metrics featuring metrics of vaccinated vs. unvaccinated patients:

Comparison Category

Results

Vaccinated patients exhibited less frequently diabetes.

(16 [16%] vs. 351 [27%], p = 0.029)

Vaccinated patients exhibited more immunosuppression.

(38 [38%] vs. 109 (8.3%), p < 0.0001)

Vaccinated patients exhibited more chronic kidney disease.

(24 [24%] vs. 89 (6.8%), p < 0.0001)

Vaccinated patients exhibited more chronic heart failure.

(16 [16%] vs. 58 [4.4%], p < 0.0001)

Vaccinated patients exhibited more chronic liver disease.

(3 [3%] vs. 8 [0.6%], p = 0.037)

Although both vaccinated and unvaccinated patients in this study experienced comparable overall SARS-CoV-2-based severity, the vaccinated cohort required less frequently IMV at ICU day 1 and during ICU stay (23 [23%] vs. 785 [59.7%], p < 0.0001, and 48 [48%] vs. 930 [70.7%], p < 0.0001, respectively).

Interestingly the French study authors write:

“There was no difference concerning ICU mortality (31 [31%] vs. 379 [28.8%], p = 0.64).

They concluded:

“Severe SARS-Cov2 infection after vaccination occurs mainly in patients with immunosuppression, chronic kidney, heart, or liver failure. Age and disease severity are independently associated with mortality.”

Lead Research/Investigator

Adrien Mirouse, University Hospitals Pitié Salpêtrière - Charles Foix (Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix) and Sorbonne Université in Paris

Alice Friol, University Hospitals Pitié Salpêtrière - Charles Foix (Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix)

Other researchers can be cited at the source.

Call to Action: Follow the link to the source.

Severe SARS-Cov2 pneumonia in vaccinated patients: a multicenter cohort study - Scientific Reports

www.nature.com

the truth starts to surface more and more...

Why Pfizer couldn't "save" India?

or "Why India did not allow Pfizer’s Covid-19 vaccine?"

CDC Reports Hundreds of Guillain-Barre Cases with mRNA COVID-19 Vaccination

Neurologic Complication Bodes Ill for mRNA Vaccine Pipeline

CDC Reports Hundreds of Guillain-Barre Cases with mRNA COVID-19 Vaccination

Neurologic Complication Bodes Ill for mRNA Vaccine Pipeline

petermcculloughmd.substack.com

By Peter A. McCullough, MD, MPH

One of the early product warnings came in July 2021 with COVID-19 vaccination was Guillain-Barre Syndrome (GBS) or life-threatening ascending paralysis with the Janssen adenoviral COVID-19 vaccine. Using VAERS, Abara et al reported 211 cases of GBS submitted from December 2020 through January 2022 occurred with mRNA vaccines (Pfizer, Moderna) presenting with symptoms 8-10 days after taking the shot.

Of note, only 16% of cases reported by the patients themselves to the CDC leaving the majority to be reported by healthcare workers or the vaccine companies. The mean age was 59 years and sadly, 10 patients died after developing GBS. All but one of these cases died on the mechanical ventilator suggesting the systemic syndrome was far more lethal than GBS survived in other conditions (West Nile virus, Campylobacter jejuni, influenza vaccine etc.) These data strongly support FDA warnings for GBS in the FAQ for EUA vaccination and in all consent forms. This illness is a disaster for so many patients causing severe short and sometimes long term disability.

Startling Evidence Suggests BioNTech and Pfizer Falsified Key Data: Part 1:

Startling Evidence Suggests BioNTech and Pfizer Falsified Key Data: Part 1

Evidence has emerged casting serious doubt over the authenticity of tests carried out by BioNTech (Marketing Authorisation Holder) and Pfizer to prove the…

www.trialsitenews.com

Evidence has emerged casting serious doubt over the authenticity of tests carried out by BioNTech (Marketing Authorisation Holder) and Pfizer to prove the fidelity of their product by demonstrating that only the spike protein of SARS-CoV-2 is expressed in cells by the nucleoside-modified mRNA Pfizer-BioNTech Covid-19 vaccine (BNT162b2).

Several Western Blot tests were conducted to evaluate the protein expression of the mRNA in HEK cells transfected with the vaccine taken from different lots. Using this technique, the expressed proteins showed up as highly unusual looking ‘bands.’

Certain independent scientific experts have described these Western blots as the “smoking gun” evidence (particularly the “duplication” of the results) which suggest that BioNTech and Pfizer falsified key data as part of their submissions to the European Medicines Agency and the Federal Drugs Agency for securing emergency use authorisation (conditional) and later marketing authorisation approval of their product.

The bombshell evidence was dropped without so much as a ripple in the sea of brewing scandals washing up on the shores of the behemoth pharmaceutical company and its partner, BioNTech. However, some in the scientific community have taken notice and written about this scandal, known on social media as #Blotgate.

The fact there could be actual evidence to prove that Pfizer and BioNTech engaged in fraud by fabricating critical data would have major ramifications. For instance, their indemnity status (protection from any legal liability resulting from deaths or injuries caused by their product) which was written into their purchasing contracts and signed by many countries, would cease to apply

VACCINES#BLOTGATE & THE UNKNOWN RISKS OF “TRUNCATED SPIKE PROTEIN”

#BLOTGATE & THE UNKNOWN RISKS OF “TRUNCATED SPIKE PROTEIN” – The Phaser

thephaser.com

Cancelled Orders—You’re Out of Luck. More Nation State & NGO Buyers Can’t Get their COVID-19 Vaccine Money Back from Pharma

Cancelled Orders—You’re Out of Luck. More Nation State & NGO Buyers Can’t Get their COVID-19 Vaccine Money Back from Pharma

Pfizer exploited its market muscle, distribution prowess, and overall leverage during the pandemic, capitalizing on desperate counties, regional blocs, and…

www.trialsitenews.com

Pfizer exploited its market muscle, distribution prowess, and overall leverage during the pandemic, capitalizing on desperate counties, regional blocs, and non-governmental organizations (NGOs) forcing the execution of adhesion-like contacts, inclusive of clauses that in some cases appear to supersede even national constitutions protections. But how could this be? Well, prey on fear, uncertainty, desperation, and perhaps, ignorance among the leaders of many nations. During the pandemic, TrialSite tracked and amplified the work of Public Citizen, a nonprofit that issued a report titled Pfizer’s Power. The well-researched output showcased an important investigation into the relationship between the Big Pharma and national governments during the pandemic. TrialSite reported ominous statements from that report such as “Five years in the future when these confidentiality agreements are over, you will learn what really happened in these negotiations.” But Public Citizen’s work did point to some answers. The nonprofit’s report showed that Pfizer has the power to “silence governments, throttle supply, shift risk, and maximize profits” during the pandemic. TrialSite also reported that even in a time of war (Russia’s invasion of Ukraine) as the impacts ripped through the economy in Eastern Europe such as in Poland, Pfizer wouldn’t budge when that country invoked emergency measures, citing the force majeure clause to back out of the vaccine procurement contract. Not a chance. Pfizer, and as it turns out most if not all of the other vaccine producers, seek only to maximize every dollar, exhibiting a totally unacceptable level of coin-operated behavior during the worst health crisis in a century. During the onset of the pandemic and the promotional buildup early on of the COVID-19 vaccines, many of the world’s government’s empowered that U.S.-based company for instance, which continues to ruthlessly run roughshod over any and all in its way.

But Pfizer is not alone, as other COVID vaccine producers and corporations that have quarterly pressure to produce financial results, collectively won’t refund Covax for what turns out to be $1.4 billion in canceled orders!

A procurement pool to distribute vaccines to low- and middle-income countries (LMICs) with an emphasis on the most economically challenged places, Covax was launched by Gavi, the Vaccine Alliance, a public-private global health partnership. Even those organizations dedicated to serving poor people worldwide are taken for all they can by profit-maximizing corporations.

A recent New York Times account reveals that the Swiss-based NGO organized to develop and distribute vaccines worldwide to the poor reached out and attempted to negotiate deals with the COVID-19 vaccine makers in a bid to get some prepayments reimbursed.

Collectively, the players involved on the pharma side generated $13.8 billion on vaccines distributed via GAVI. But despite cancelled orders, GAVI won’t be getting any money back.

References

Vaccine Makers Kept $1.4 Billion in Prepayments for Canceled Covid Shots for the World’s Poor

Separately, Johnson & Johnson is demanding additional payment for unwanted shots, confidential documents show.

www.nytimes.com